Blood Stem Cell Transplant Superior to DMDs in Highly Active RRMS, MIST Trial Shows

Stuart SchlossmanAdditional MS resource sites, MS Research Study and Reports, Stem Cell Related

April 23, 2018

HSCT













 Autologous non-myeloablative hematopoietic stem cell transplant was found to be significantly better at reducing risks for disability in relapsing-remitting multiple sclerosis (RRMS) patients compared to disease-modifying drug (DMD) therapies, interim results of the MIST clinical trial show.


READ MORE




::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews